NCT03963076

Brief Summary

Prospective multicentric study. 60 subjects with allergic rhinitis will be enrolled to test the efficacy of nasal hypertonic spray Puressentiel on symptoms of allergic rhinitis and nasal peak flow. Subjects with allergic rhinitis and nasal obstruction will use during 30 days the nasal spray (2 nebulisations /day in each nostril) during 30 days. Rhinitis symptoms questionnaire and nasal inspiratory peak flow will be evaluated before and after 30 days of exposure.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2019

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

May 18, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 24, 2019

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2019

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2019

Completed
Last Updated

May 24, 2019

Status Verified

May 1, 2019

Enrollment Period

5 months

First QC Date

May 18, 2019

Last Update Submit

May 23, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • Rhinitis auto questionnaire symptoms

    5 questions quoted from 1 (worse) to 5 (best).

    Measurement at Day 0

  • Rhinitis auto questionnaire symptoms

    5 questions quoted from 1 (worse) to 5 (best).

    Measurement at Day 30

Secondary Outcomes (2)

  • Nasal inspiratory peak flow

    Measurement at Day 0 and Day 30

  • Nasal inspiratory peak flow

    Measurement at Day 30

Study Arms (1)

allergic rhinitis

EXPERIMENTAL

administration of a nasal hypertonic spray twice a day for one month

Other: nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)

Interventions

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • allergic rhinitis with nasal obstruction

You may not qualify if:

  • pregnant patients
  • patients with severe asthma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Caroline Bonnard

Paris, 75016, France

RECRUITING

MeSH Terms

Conditions

Rhinitis, Allergic

Interventions

Oils, Volatile

Condition Hierarchy (Ancestors)

RhinitisNose DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityOtorhinolaryngologic DiseasesHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

OilsLipids

Central Study Contacts

pascal Demoly, MD, PhD

CONTACT

Caroline Bonnard, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: prospective multicentric study
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 18, 2019

First Posted

May 24, 2019

Study Start

May 1, 2019

Primary Completion

September 30, 2019

Study Completion

October 31, 2019

Last Updated

May 24, 2019

Record last verified: 2019-05

Data Sharing

IPD Sharing
Will not share

Locations